12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

OncoSec Medical System regulatory update

In 2011, OncoSec acquired from Inovio Pharmaceuticals Inc. (NYSE-M:INO, Blue Bell, Pa.) selective electrochemical tumor ablation (SECTA) technology, which is used in the OMS device (see BioCentury, April 11, 2011).

OncoSec Medical...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >